[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fJU-4UJvLff34lyCvSG_OP8cZvk1ze2GYbiaTiwU4B34":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":86,"rows":93},"National Cancer Center, Korea",[4],200,false,36,24,77513,16,107,[14,17,19,22,25,28,31,34],{"name":15,"count":16},"Breast Cancer",20,{"name":18,"count":11},"Gastric Cancer",{"name":20,"count":21},"Lung Cancer",13,{"name":23,"count":24},"Pancreatic Cancer",11,{"name":26,"count":27},"Early Gastric Cancer",10,{"name":29,"count":30},"Rectal Cancer",7,{"name":32,"count":33},"Metastatic Breast Cancer",6,{"name":35,"count":36},"Stomach Neoplasms",5,[38,43,48,53,58,63,68,73,78,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02407119","Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD","2016-06","7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT01678027","Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication","2018-12","LAC triple therapy",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06135896","Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","2026-06-30","Tripegfilgrastim",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06156527","A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker","2026-09-05","Lazertinib",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03756298","Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","2026-12-31","Atezolizumab",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05036434","Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma","2027-02-28","Pembrolizumab \u002F Lenvatinib",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT07121478","Patients With High-grade Pancreatic Neuroendocrine Tumors","2027-03-01","Lurbinectedin 4 MG Injection [Zepzelca]",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT05827523","Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS \u002F KOV-HIPEC-04)","2027-12-31","Cisplatin",{"nctId":79,"briefTitle":80,"date":76,"intervention":81},"NCT06971965","Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.","Levothyroxin",{"nctId":83,"briefTitle":84,"date":76,"intervention":85},"NCT06388720","The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy","Mitomycin-C",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,182,206,228,252,278,338,379,408,429,455,478,496,520,541,559,582,606,652,688,714,732,750,777,795,821,839,862,888,915,933,958,1009,1049,1099,1143,1174,1208,1230,1248,1266,1284,1302,1325,1352,1376,1401,1419,1437,1455,1473,1498,1523,1541,1565,1583,1607,1629,1653,1677,1704,1728,1753,1771,1794,1820,1838,1862,1885,1909,1932,1955,1973,1991,2009,2034,2052,2076,2094,2117,2141,2159,2182,2206,2231,2249,2272,2297,2315,2338,2356,2380,2398,2420,2442,2464,2487,2509,2527,2562,2592,2626],{"intervention":77,"totalTrials":33,"cells":95},{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":166,"PHASE4":178,"NA":180},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[103,117,129,141,154],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"NCT00452634","Irinotecan\u002FCisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)","COMPLETED",[89],"2009-11","2010-05","2006-04",62,[113],"Small Cell Lung Cancer",[115,77,116],"Irinotecan","Simvastatin",{"nctId":118,"briefTitle":119,"status":120,"phases":121,"primaryCompletion":122,"start":123,"enrollment":124,"conditions":125,"interventions":126},"NCT00398385","Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer","UNKNOWN",[89],"2010-04","2005-05",170,[20],[127,128],"cisplatin","gemcitabine hydrochloride",{"nctId":130,"briefTitle":131,"status":120,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":139},"NCT00874328","A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB\u002FIV Non Small Cell Lung Cancer (NSCLC)",[88,89],"2011-12","2012-12","2008-10",74,[138],"Advanced Non-Small Cell Lung Cancer",[115,77,140],"TS-1",{"nctId":142,"briefTitle":143,"status":144,"phases":145,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":151},"NCT01939418","Phase Ib\u002FII Trials of RAD001 in Triple Negative Metastatic Breast Cancer","TERMINATED",[88,89],"2016-07-30","2017-07-30","2013-08",23,[32],[152,153,77],"RAD001","Gemcitabine",{"nctId":155,"briefTitle":156,"status":120,"phases":157,"primaryCompletion":158,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":163},"NCT00452881","Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB\u002FII\u002FIIIA NSCLC",[89],"2009-10","2014-12","2006-05",151,[20],[164,165,77],"gemcitabine","Oxaliplatin",{"trials":167,"activeCount":177,"soonestReadout":76},[168],{"nctId":74,"briefTitle":75,"status":169,"phases":170,"primaryCompletion":76,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":176},"RECRUITING",[90],"2030-12-31","2023-05-31",520,[175],"Ovarian Cancer",[77],1,{"trials":179,"activeCount":98},[],{"trials":181,"activeCount":98},[],{"intervention":47,"totalTrials":177,"cells":183},{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":202,"NA":204},{"trials":185,"activeCount":98},[],{"trials":187,"activeCount":98},[],{"trials":189,"activeCount":98},[],{"trials":191,"activeCount":177,"soonestReadout":46},[192],{"nctId":44,"briefTitle":45,"status":193,"phases":194,"primaryCompletion":46,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":201},"ACTIVE_NOT_RECRUITING",[90],"2035-12","2004-11",1838,[18,199,200],"Helicobacter Pylori Infection","Family Members",[47],{"trials":203,"activeCount":98},[],{"trials":205,"activeCount":98},[],{"intervention":42,"totalTrials":177,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":224,"NA":226},{"trials":209,"activeCount":98},[],{"trials":211,"activeCount":98},[],{"trials":213,"activeCount":98},[],{"trials":215,"activeCount":177,"soonestReadout":41},[216],{"nctId":39,"briefTitle":40,"status":193,"phases":217,"primaryCompletion":41,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},[90],"2030-06","2003-06",470,[199,26,222],"Endoscopic Resection",[42],{"trials":225,"activeCount":98},[],{"trials":227,"activeCount":98},[],{"intervention":229,"totalTrials":177,"cells":230},"10-day bismuth-based quadruple therapy",{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":248,"NA":250},{"trials":232,"activeCount":98},[],{"trials":234,"activeCount":98},[],{"trials":236,"activeCount":98},[],{"trials":238,"activeCount":177,"soonestReadout":243},[239],{"nctId":240,"briefTitle":241,"status":193,"phases":242,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":247},"NCT02112214","Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population",[90],"2029-12","2014-06",5224,[18,199],[229],{"trials":249,"activeCount":98},[],{"trials":251,"activeCount":98},[],{"intervention":253,"totalTrials":177,"cells":254},"Aspirin 100mg",{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":274,"NA":276},{"trials":256,"activeCount":98},[],{"trials":258,"activeCount":98},[],{"trials":260,"activeCount":98},[],{"trials":262,"activeCount":177,"soonestReadout":267},[263],{"nctId":264,"briefTitle":265,"status":169,"phases":266,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":273},"NCT04214990","Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients",[90],"2031-03-31","2032-03-31","2020-02-15",1700,[272,18],"Aspirin",[253],{"trials":275,"activeCount":98},[],{"trials":277,"activeCount":98},[],{"intervention":153,"totalTrials":33,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":332,"PHASE4":334,"NA":336},{"trials":281,"activeCount":98},[],{"trials":283,"activeCount":98},[],{"trials":285,"activeCount":177,"soonestReadout":76},[286,296,300,311,320,328],{"nctId":287,"briefTitle":288,"status":106,"phases":289,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":295},"NCT01043172","A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection",[89],"2016-12-31","2009-07-20",72,[294],"Cholangiocarcinoma",[153],{"nctId":142,"briefTitle":143,"status":144,"phases":297,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":298,"interventions":299},[88,89],[32],[152,153,77],{"nctId":301,"briefTitle":302,"status":106,"phases":303,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":309},"NCT00453167","Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer",[89],"2009-12","2010-03","2005-12",35,[20],[310,153],"Paclitaxel",{"nctId":312,"briefTitle":313,"status":120,"phases":314,"primaryCompletion":109,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":319},"NCT00453115","Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB\u002FIV Non Small Cell Lung Cancer (NSCLC)",[89],"2011-05","2006-01",43,[20],[165,153],{"nctId":83,"briefTitle":84,"status":169,"phases":321,"primaryCompletion":76,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":327},[89],"2028-12-31","2024-11-19",82,[326],"Bladder Cancer",[85,164],{"nctId":155,"briefTitle":156,"status":120,"phases":329,"primaryCompletion":158,"completion":159,"start":160,"enrollment":161,"conditions":330,"interventions":331},[89],[20],[164,165,77],{"trials":333,"activeCount":98},[],{"trials":335,"activeCount":98},[],{"trials":337,"activeCount":98},[],{"intervention":339,"totalTrials":340,"cells":341},"Capecitabine",3,{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":373,"PHASE4":375,"NA":377},{"trials":343,"activeCount":98},[],{"trials":345,"activeCount":98},[],{"trials":347,"activeCount":177,"soonestReadout":61},[348,357,366],{"nctId":349,"briefTitle":350,"status":120,"phases":351,"primaryCompletion":352,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":356},"NCT00658840","Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma",[89],"2013-06","2006-06",55,[23],[339],{"nctId":358,"briefTitle":359,"status":120,"phases":360,"primaryCompletion":304,"completion":361,"start":353,"enrollment":362,"conditions":363,"interventions":365},"NCT00453323","Paclitaxel and Capecitabine in Patients With Metastatic\u002FRecurrence Esophageal Cancer",[89],"2010-12",33,[364],"Esophageal Cancer",[310,339],{"nctId":59,"briefTitle":60,"status":193,"phases":367,"primaryCompletion":61,"completion":76,"start":368,"enrollment":369,"conditions":370,"interventions":372},[89],"2019-01-15",284,[371],"Triple Negative Breast Cancer",[62,339],{"trials":374,"activeCount":98},[],{"trials":376,"activeCount":98},[],{"trials":378,"activeCount":98},[],{"intervention":62,"totalTrials":380,"cells":381},2,{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":383,"activeCount":98},[],{"trials":385,"activeCount":98},[],{"trials":387,"activeCount":177,"soonestReadout":61},[388,398],{"nctId":389,"briefTitle":390,"status":120,"phases":391,"primaryCompletion":392,"completion":393,"start":394,"enrollment":307,"conditions":395,"interventions":397},"NCT03262454","Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC",[89],"2023-02-23","2024-07-31","2018-01-22",[396],"Small Cell Lung Cancer Recurrent",[62],{"nctId":59,"briefTitle":60,"status":193,"phases":399,"primaryCompletion":61,"completion":76,"start":368,"enrollment":369,"conditions":400,"interventions":401},[89],[371],[62,339],{"trials":403,"activeCount":98},[],{"trials":405,"activeCount":98},[],{"trials":407,"activeCount":98},[],{"intervention":67,"totalTrials":177,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":423,"PHASE4":425,"NA":427},{"trials":411,"activeCount":98},[],{"trials":413,"activeCount":98},[],{"trials":415,"activeCount":177,"soonestReadout":66},[416],{"nctId":64,"briefTitle":65,"status":193,"phases":417,"primaryCompletion":66,"completion":66,"start":418,"enrollment":419,"conditions":420,"interventions":422},[89],"2021-11-15",30,[421],"Adrenocortical Carcinoma",[67],{"trials":424,"activeCount":98},[],{"trials":426,"activeCount":98},[],{"trials":428,"activeCount":98},[],{"intervention":430,"totalTrials":177,"cells":431},"Lenvatinib",{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":449,"PHASE4":451,"NA":453},{"trials":433,"activeCount":98},[],{"trials":435,"activeCount":98},[],{"trials":437,"activeCount":177,"soonestReadout":443},[438],{"nctId":439,"briefTitle":440,"status":441,"phases":442,"primaryCompletion":443,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":448},"NCT07297654","First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment","NOT_YET_RECRUITING",[89],"2028-05","2026-02",50,[447],"Advanced Hepatocellular Carcinoma",[430],{"trials":450,"activeCount":98},[],{"trials":452,"activeCount":98},[],{"trials":454,"activeCount":98},[],{"intervention":52,"totalTrials":177,"cells":456},{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":472,"PHASE4":474,"NA":476},{"trials":458,"activeCount":98},[],{"trials":460,"activeCount":98},[],{"trials":462,"activeCount":177,"soonestReadout":51},[463],{"nctId":49,"briefTitle":50,"status":169,"phases":464,"primaryCompletion":51,"completion":51,"start":465,"enrollment":466,"conditions":467,"interventions":471},[89],"2024-01-16",98,[468,469,470],"Unresectable Pancreatic Cancer","Unresectable Bile Duct Carcinoma","Unresectable Biliary Tract Carcinoma",[52],{"trials":473,"activeCount":98},[],{"trials":475,"activeCount":98},[],{"trials":477,"activeCount":98},[],{"intervention":85,"totalTrials":177,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":481,"activeCount":98},[],{"trials":483,"activeCount":98},[],{"trials":485,"activeCount":177,"soonestReadout":76},[486],{"nctId":83,"briefTitle":84,"status":169,"phases":487,"primaryCompletion":76,"completion":322,"start":323,"enrollment":324,"conditions":488,"interventions":489},[89],[326],[85,164],{"trials":491,"activeCount":98},[],{"trials":493,"activeCount":98},[],{"trials":495,"activeCount":98},[],{"intervention":72,"totalTrials":177,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":514,"PHASE4":516,"NA":518},{"trials":499,"activeCount":98},[],{"trials":501,"activeCount":98},[],{"trials":503,"activeCount":177,"soonestReadout":71},[504],{"nctId":69,"briefTitle":70,"status":505,"phases":506,"primaryCompletion":71,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":513},"ENROLLING_BY_INVITATION",[89],"2029-12-31","2025-09-23",46,[511,512],"Neuroendocrine Tumor of Pancreas","Pancreatic Neuroendocrine Tumors",[72],{"trials":515,"activeCount":98},[],{"trials":517,"activeCount":98},[],{"trials":519,"activeCount":98},[],{"intervention":57,"totalTrials":177,"cells":521},{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":535,"PHASE4":537,"NA":539},{"trials":523,"activeCount":98},[],{"trials":525,"activeCount":98},[],{"trials":527,"activeCount":177,"soonestReadout":56},[528],{"nctId":54,"briefTitle":55,"status":169,"phases":529,"primaryCompletion":56,"completion":61,"start":530,"enrollment":531,"conditions":532,"interventions":533},[89],"2023-09-05",120,[57],[57,534],"Bevacizumab Injectable Product",{"trials":536,"activeCount":98},[],{"trials":538,"activeCount":98},[],{"trials":540,"activeCount":98},[],{"intervention":534,"totalTrials":177,"cells":542},{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":544,"activeCount":98},[],{"trials":546,"activeCount":98},[],{"trials":548,"activeCount":177,"soonestReadout":56},[549],{"nctId":54,"briefTitle":55,"status":169,"phases":550,"primaryCompletion":56,"completion":61,"start":530,"enrollment":531,"conditions":551,"interventions":552},[89],[57],[57,534],{"trials":554,"activeCount":98},[],{"trials":556,"activeCount":98},[],{"trials":558,"activeCount":98},[],{"intervention":81,"totalTrials":177,"cells":560},{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":567,"PHASE4":569,"NA":571},{"trials":562,"activeCount":98},[],{"trials":564,"activeCount":98},[],{"trials":566,"activeCount":98},[],{"trials":568,"activeCount":98},[],{"trials":570,"activeCount":98},[],{"trials":572,"activeCount":177,"soonestReadout":76},[573],{"nctId":79,"briefTitle":80,"status":441,"phases":574,"primaryCompletion":76,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":581},[92],"2032-12-31","2025-06-02",578,[579,580],"Thyroid Cancer","Papillary Thyroid Carcinoma",[81],{"intervention":583,"totalTrials":177,"cells":584},"Cancer pain management",{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":593,"NA":604},{"trials":586,"activeCount":98},[],{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":98},[],{"trials":592,"activeCount":98},[],{"trials":594,"activeCount":98},[595],{"nctId":596,"briefTitle":597,"status":106,"phases":598,"primaryCompletion":361,"completion":361,"start":599,"enrollment":600,"conditions":601,"interventions":603},"NCT01043068","The Effect of Cancer Pain Management Protocol on Hospitalized Cancer Patients: A Pilot Study",[91],"2010-01",25,[602],"Cancers, Pain",[583],{"trials":605,"activeCount":98},[],{"intervention":607,"totalTrials":340,"cells":608},"Gefitinib",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":628,"PHASE4":648,"NA":650},{"trials":610,"activeCount":98},[],{"trials":612,"activeCount":98},[],{"trials":614,"activeCount":98},[615],{"nctId":616,"briefTitle":617,"status":120,"phases":618,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":623,"interventions":626},"NCT01502202","Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers",[89],"2014-08","2015-02","2012-03",162,[624,625],"Non Small Cell Lung Cancer","Adenocarcinoma",[607,627],"Pemetrexed plusCIsplatin",{"trials":629,"activeCount":98},[630,638],{"nctId":631,"briefTitle":632,"status":106,"phases":633,"primaryCompletion":108,"completion":305,"start":634,"enrollment":635,"conditions":636,"interventions":637},"NCT00455936","First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker",[90],"2005-10",315,[20],[607],{"nctId":639,"briefTitle":640,"status":120,"phases":641,"start":642,"enrollment":643,"conditions":644,"interventions":645},"NCT00955695","Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer",[90],"2009-05",242,[20],[646,647],"erlotinib hydrochloride","gefitinib",{"trials":649,"activeCount":98},[],{"trials":651,"activeCount":98},[],{"intervention":653,"totalTrials":380,"cells":654},"Irinotecan, Capecitabine",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":659,"PHASE3":673,"PHASE4":684,"NA":686},{"trials":656,"activeCount":98},[],{"trials":658,"activeCount":98},[],{"trials":660,"activeCount":98},[661],{"nctId":662,"briefTitle":663,"status":144,"phases":664,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":672},"NCT00506168","Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer",[89],"2007-07","2001-11",37,[669,670,671],"Colorectal Neoplasms","Secondary","Drug Therapy, Combination",[653],{"trials":674,"activeCount":98},[675],{"nctId":676,"briefTitle":677,"status":120,"phases":678,"primaryCompletion":679,"completion":679,"start":680,"enrollment":681,"conditions":682,"interventions":683},"NCT01501669","Irinotecan\u002FCapecitabine Versus Capecitabine in Patients Treated With A\u002FT for HER2 Negative Metastatic Breast Cancer",[90],"2014-02","2011-06",222,[32],[653],{"trials":685,"activeCount":98},[],{"trials":687,"activeCount":98},[],{"intervention":689,"totalTrials":177,"cells":690},"Standard triple therapy",{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":697,"PHASE4":710,"NA":712},{"trials":692,"activeCount":98},[],{"trials":694,"activeCount":98},[],{"trials":696,"activeCount":98},[],{"trials":698,"activeCount":98},[699],{"nctId":700,"briefTitle":701,"status":106,"phases":702,"primaryCompletion":46,"completion":703,"start":704,"enrollment":705,"conditions":706,"interventions":708},"NCT02557932","Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication",[90],"2019-09-28","2015-09",352,[199,707],"Family History of Stomach Cancer",[689,709],"Bismuth quadruple therapy",{"trials":711,"activeCount":98},[],{"trials":713,"activeCount":98},[],{"intervention":709,"totalTrials":177,"cells":715},{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":722,"PHASE4":728,"NA":730},{"trials":717,"activeCount":98},[],{"trials":719,"activeCount":98},[],{"trials":721,"activeCount":98},[],{"trials":723,"activeCount":98},[724],{"nctId":700,"briefTitle":701,"status":106,"phases":725,"primaryCompletion":46,"completion":703,"start":704,"enrollment":705,"conditions":726,"interventions":727},[90],[199,707],[689,709],{"trials":729,"activeCount":98},[],{"trials":731,"activeCount":98},[],{"intervention":646,"totalTrials":177,"cells":733},{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":740,"PHASE4":746,"NA":748},{"trials":735,"activeCount":98},[],{"trials":737,"activeCount":98},[],{"trials":739,"activeCount":98},[],{"trials":741,"activeCount":98},[742],{"nctId":639,"briefTitle":640,"status":120,"phases":743,"start":642,"enrollment":643,"conditions":744,"interventions":745},[90],[20],[646,647],{"trials":747,"activeCount":98},[],{"trials":749,"activeCount":98},[],{"intervention":751,"totalTrials":177,"cells":752},"I131",{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":759,"PHASE4":773,"NA":775},{"trials":754,"activeCount":98},[],{"trials":756,"activeCount":98},[],{"trials":758,"activeCount":98},[],{"trials":760,"activeCount":98},[761],{"nctId":762,"briefTitle":763,"status":120,"phases":764,"primaryCompletion":765,"completion":766,"start":767,"enrollment":768,"conditions":769,"interventions":771},"NCT02418247","Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer",[89,90],"2017-12","2020-12","2013-05",556,[770],"Thyroid Neoplasms",[751,772],"I123",{"trials":774,"activeCount":98},[],{"trials":776,"activeCount":98},[],{"intervention":772,"totalTrials":177,"cells":778},{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":785,"PHASE4":791,"NA":793},{"trials":780,"activeCount":98},[],{"trials":782,"activeCount":98},[],{"trials":784,"activeCount":98},[],{"trials":786,"activeCount":98},[787],{"nctId":762,"briefTitle":763,"status":120,"phases":788,"primaryCompletion":765,"completion":766,"start":767,"enrollment":768,"conditions":789,"interventions":790},[89,90],[770],[751,772],{"trials":792,"activeCount":98},[],{"trials":794,"activeCount":98},[],{"intervention":796,"totalTrials":177,"cells":797},"Ferinject®",{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":802,"PHASE3":804,"PHASE4":817,"NA":819},{"trials":799,"activeCount":98},[],{"trials":801,"activeCount":98},[],{"trials":803,"activeCount":98},[],{"trials":805,"activeCount":98},[806],{"nctId":807,"briefTitle":808,"status":106,"phases":809,"primaryCompletion":810,"completion":810,"start":811,"enrollment":812,"conditions":813,"interventions":815},"NCT01725789","Ferinject® Assessment In GastRectomy Patients With Acute Isovolemic Anemia (FAIRY)",[90],"2016-04","2012-11",454,[814],"Anemia",[796,816],"normal saline",{"trials":818,"activeCount":98},[],{"trials":820,"activeCount":98},[],{"intervention":816,"totalTrials":177,"cells":822},{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":829,"PHASE4":835,"NA":837},{"trials":824,"activeCount":98},[],{"trials":826,"activeCount":98},[],{"trials":828,"activeCount":98},[],{"trials":830,"activeCount":98},[831],{"nctId":807,"briefTitle":808,"status":106,"phases":832,"primaryCompletion":810,"completion":810,"start":811,"enrollment":812,"conditions":833,"interventions":834},[90],[814],[796,816],{"trials":836,"activeCount":98},[],{"trials":838,"activeCount":98},[],{"intervention":840,"totalTrials":177,"cells":841},"Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine",{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":858,"NA":860},{"trials":843,"activeCount":98},[],{"trials":845,"activeCount":98},[],{"trials":847,"activeCount":98},[],{"trials":849,"activeCount":98},[850],{"nctId":851,"briefTitle":852,"status":106,"phases":853,"primaryCompletion":634,"completion":316,"start":854,"enrollment":855,"conditions":856,"interventions":857},"NCT00352378","Primary Chemotherapy With Adriamycin\u002FCyclophosphamide(AC) vs Taxotere\u002FXeloda(TX) for Stage II and III Breast Cancer",[90],"2002-06",209,[15],[840],{"trials":859,"activeCount":98},[],{"trials":861,"activeCount":98},[],{"intervention":863,"totalTrials":177,"cells":864},"Proton pump inhibitor",{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":884,"NA":886},{"trials":866,"activeCount":98},[],{"trials":868,"activeCount":98},[],{"trials":870,"activeCount":98},[],{"trials":872,"activeCount":98},[873],{"nctId":874,"briefTitle":875,"status":144,"phases":876,"primaryCompletion":877,"completion":878,"start":879,"enrollment":880,"conditions":881,"interventions":883},"NCT02150447","The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding",[90],"2015-04","2017-05","2009-06",394,[18,882],"Bleeding",[863],{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":98},[],{"intervention":889,"totalTrials":177,"cells":890},"HAPREP®",{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":897,"PHASE4":911,"NA":913},{"trials":892,"activeCount":98},[],{"trials":894,"activeCount":98},[],{"trials":896,"activeCount":98},[],{"trials":898,"activeCount":98},[899],{"nctId":900,"briefTitle":901,"status":106,"phases":902,"primaryCompletion":903,"completion":904,"start":905,"enrollment":906,"conditions":907,"interventions":909},"NCT02551198","Comparison of Polyethylene Glycol With Ascorbic Acid and Oral Sulfate Solution for Bowel Preparation",[90],"2016-03-01","2017-09-01","2015-11-01",184,[908],"Healthy",[889,910],"SUCLEAR®",{"trials":912,"activeCount":98},[],{"trials":914,"activeCount":98},[],{"intervention":910,"totalTrials":177,"cells":916},{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":923,"PHASE4":929,"NA":931},{"trials":918,"activeCount":98},[],{"trials":920,"activeCount":98},[],{"trials":922,"activeCount":98},[],{"trials":924,"activeCount":98},[925],{"nctId":900,"briefTitle":901,"status":106,"phases":926,"primaryCompletion":903,"completion":904,"start":905,"enrollment":906,"conditions":927,"interventions":928},[90],[908],[889,910],{"trials":930,"activeCount":98},[],{"trials":932,"activeCount":98},[],{"intervention":934,"totalTrials":177,"cells":935},"bupivacaine",{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":942,"PHASE4":954,"NA":956},{"trials":937,"activeCount":98},[],{"trials":939,"activeCount":98},[],{"trials":941,"activeCount":98},[],{"trials":943,"activeCount":98},[944],{"nctId":945,"briefTitle":946,"status":106,"phases":947,"primaryCompletion":621,"completion":948,"start":949,"enrollment":950,"conditions":951,"interventions":953},"NCT01423292","Ultrasound Guided Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection",[90],"2012-04","2011-08",56,[952],"Laparoscopic Colecctomy",[934],{"trials":955,"activeCount":98},[],{"trials":957,"activeCount":98},[],{"intervention":959,"totalTrials":340,"cells":960},"Docetaxel",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":962,"activeCount":98},[],{"trials":964,"activeCount":98},[],{"trials":966,"activeCount":98},[967,982,994],{"nctId":968,"briefTitle":969,"status":120,"phases":970,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":975,"interventions":977},"NCT03497702","Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive\u002FHER-2 Negative Breast Cancer",[89],"2023-11","2024-01","2017-05-08",114,[15,976],"Invasive Breast Cancer",[978,979,959,980,981],"Doxorubicin","Cyclophosphamide","Letrozole","leuprorelin",{"nctId":983,"briefTitle":984,"status":120,"phases":985,"primaryCompletion":986,"completion":315,"start":987,"enrollment":988,"conditions":989,"interventions":990},"NCT00980603","Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer",[89],"2010-11","2008-11",144,[18],[991,992,993],"docetaxel","docetaxel, cisplatin","docetaxel, S-1",{"nctId":995,"briefTitle":996,"status":120,"phases":997,"primaryCompletion":998,"completion":159,"start":999,"enrollment":307,"conditions":1000,"interventions":1002},"NCT01380275","Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.",[89],"2014-09","2008-04",[1001],"Sarcoma",[959,115],{"trials":1004,"activeCount":98},[],{"trials":1006,"activeCount":98},[],{"trials":1008,"activeCount":98},[],{"intervention":1010,"totalTrials":340,"cells":1011},"simvastatin",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1043,"PHASE4":1045,"NA":1047},{"trials":1013,"activeCount":98},[],{"trials":1015,"activeCount":98},[],{"trials":1017,"activeCount":98},[1018,1022,1032],{"nctId":104,"briefTitle":105,"status":106,"phases":1019,"primaryCompletion":108,"completion":109,"start":110,"enrollment":111,"conditions":1020,"interventions":1021},[89],[113],[115,77,116],{"nctId":1023,"briefTitle":1024,"status":106,"phases":1025,"primaryCompletion":1026,"completion":1027,"start":160,"enrollment":1028,"conditions":1029,"interventions":1030},"NCT00452244","Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)",[89],"2011-02","2011-03",110,[20],[1010,1031],"gefitinib only",{"nctId":1033,"briefTitle":1034,"status":106,"phases":1035,"primaryCompletion":290,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1041},"NCT01156545","BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC",[89],"2021-06-09","2010-10",68,[1040],"Non-small Cell Lung Cancer",[1042,1010],"BIBW 2992",{"trials":1044,"activeCount":98},[],{"trials":1046,"activeCount":98},[],{"trials":1048,"activeCount":98},[],{"intervention":1050,"totalTrials":340,"cells":1051},"Erlotinib",{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1093,"PHASE4":1095,"NA":1097},{"trials":1053,"activeCount":98},[],{"trials":1055,"activeCount":98},[],{"trials":1057,"activeCount":98},[1058,1070,1082],{"nctId":1059,"briefTitle":1060,"status":120,"phases":1061,"primaryCompletion":1062,"completion":1062,"start":1063,"enrollment":1064,"conditions":1065,"interventions":1067},"NCT00620269","Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III",[89],"2015-03","2008-02",212,[20,1066],"NSCLC",[1050,1068,1069],"Induction or consolidation IP chemotherapy","CCRT with IP chemotherapy",{"nctId":1071,"briefTitle":1072,"status":120,"phases":1073,"primaryCompletion":1074,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1081},"NCT01470716","Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations",[89],"2021-12-31","2022-06-30","2012-01",26,[1079,1080],"NSCLC Stage II","NSCLC, Stage IIIA",[1050],{"nctId":1083,"briefTitle":1084,"status":120,"phases":1085,"primaryCompletion":1074,"completion":1086,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1091},"NCT03126799","A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)",[89],"2023-07-20","2016-11-01",128,[1090],"EGFR Positive Non-small Cell Lung Cancer",[1092,1050],"Erlotinib plus Bevacizumab",{"trials":1094,"activeCount":98},[],{"trials":1096,"activeCount":98},[],{"trials":1098,"activeCount":98},[],{"intervention":1100,"totalTrials":340,"cells":1101},"indocyanine green",{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1137,"PHASE4":1139,"NA":1141},{"trials":1103,"activeCount":98},[],{"trials":1105,"activeCount":98},[],{"trials":1107,"activeCount":98},[1108,1118,1130],{"nctId":1109,"briefTitle":1110,"status":120,"phases":1111,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":1116,"interventions":1117},"NCT02817334","A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery in Breast Cancer",[89],"2016-09","2016-12","2016-03",149,[15],[1100],{"nctId":1119,"briefTitle":1120,"status":106,"phases":1121,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":1125,"conditions":1126,"interventions":1127},"NCT02479997","Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients",[89],"2018-03-08","2018-03-27","2015-03-31",130,[15],[1128,1129],"Indocyanine green","Radioisotope",{"nctId":1131,"briefTitle":1132,"status":120,"phases":1133,"primaryCompletion":1134,"completion":1134,"start":1062,"enrollment":36,"conditions":1135,"interventions":1136},"NCT02473159","Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Breast Cancer",[89],"2015-12",[15],[1100],{"trials":1138,"activeCount":98},[],{"trials":1140,"activeCount":98},[],{"trials":1142,"activeCount":98},[],{"intervention":310,"totalTrials":340,"cells":1144},{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1149,"PHASE3":1168,"PHASE4":1170,"NA":1172},{"trials":1146,"activeCount":98},[],{"trials":1148,"activeCount":98},[],{"trials":1150,"activeCount":98},[1151,1160,1164],{"nctId":1152,"briefTitle":1153,"status":1154,"phases":1155,"primaryCompletion":1156,"completion":135,"start":665,"enrollment":98,"conditions":1157,"interventions":1158},"NCT01169870","Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients","WITHDRAWN",[89],"2008-08",[15],[1159,310],"Genexol-PM",{"nctId":301,"briefTitle":302,"status":106,"phases":1161,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":1162,"interventions":1163},[89],[20],[310,153],{"nctId":358,"briefTitle":359,"status":120,"phases":1165,"primaryCompletion":304,"completion":361,"start":353,"enrollment":362,"conditions":1166,"interventions":1167},[89],[364],[310,339],{"trials":1169,"activeCount":98},[],{"trials":1171,"activeCount":98},[],{"trials":1173,"activeCount":98},[],{"intervention":1175,"totalTrials":380,"cells":1176},"S-1, Irinotecan, Oxaliplatin",{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1190,"PHASE3":1202,"PHASE4":1204,"NA":1206},{"trials":1178,"activeCount":98},[],{"trials":1180,"activeCount":98},[1181],{"nctId":1182,"briefTitle":1183,"status":120,"phases":1184,"completion":304,"start":1185,"enrollment":149,"conditions":1186,"interventions":1189},"NCT00506207","A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy",[88],"2006-09",[1187,1188,670],"Colorectal Neoplasm","Gastric Neoplasm",[1175],{"trials":1191,"activeCount":98},[1192],{"nctId":1193,"briefTitle":1194,"status":120,"phases":1195,"completion":1196,"start":665,"enrollment":1197,"conditions":1198,"interventions":1200},"NCT00506571","Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer",[89],"2010-06",42,[1199,670],"Colorecal Neoplasms",[1201],"S-1, irinotecan, oxaliplatin",{"trials":1203,"activeCount":98},[],{"trials":1205,"activeCount":98},[],{"trials":1207,"activeCount":98},[],{"intervention":165,"totalTrials":380,"cells":1209},{"EARLY_PHASE1":1210,"PHASE1":1212,"PHASE2":1214,"PHASE3":1224,"PHASE4":1226,"NA":1228},{"trials":1211,"activeCount":98},[],{"trials":1213,"activeCount":98},[],{"trials":1215,"activeCount":98},[1216,1220],{"nctId":312,"briefTitle":313,"status":120,"phases":1217,"primaryCompletion":109,"completion":315,"start":316,"enrollment":317,"conditions":1218,"interventions":1219},[89],[20],[165,153],{"nctId":155,"briefTitle":156,"status":120,"phases":1221,"primaryCompletion":158,"completion":159,"start":160,"enrollment":161,"conditions":1222,"interventions":1223},[89],[20],[164,165,77],{"trials":1225,"activeCount":98},[],{"trials":1227,"activeCount":98},[],{"trials":1229,"activeCount":98},[],{"intervention":978,"totalTrials":177,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1233,"activeCount":98},[],{"trials":1235,"activeCount":98},[],{"trials":1237,"activeCount":98},[1238],{"nctId":968,"briefTitle":969,"status":120,"phases":1239,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":1240,"interventions":1241},[89],[15,976],[978,979,959,980,981],{"trials":1243,"activeCount":98},[],{"trials":1245,"activeCount":98},[],{"trials":1247,"activeCount":98},[],{"intervention":979,"totalTrials":177,"cells":1249},{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1260,"PHASE4":1262,"NA":1264},{"trials":1251,"activeCount":98},[],{"trials":1253,"activeCount":98},[],{"trials":1255,"activeCount":98},[1256],{"nctId":968,"briefTitle":969,"status":120,"phases":1257,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":1258,"interventions":1259},[89],[15,976],[978,979,959,980,981],{"trials":1261,"activeCount":98},[],{"trials":1263,"activeCount":98},[],{"trials":1265,"activeCount":98},[],{"intervention":980,"totalTrials":177,"cells":1267},{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1278,"PHASE4":1280,"NA":1282},{"trials":1269,"activeCount":98},[],{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[1274],{"nctId":968,"briefTitle":969,"status":120,"phases":1275,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":1276,"interventions":1277},[89],[15,976],[978,979,959,980,981],{"trials":1279,"activeCount":98},[],{"trials":1281,"activeCount":98},[],{"trials":1283,"activeCount":98},[],{"intervention":981,"totalTrials":177,"cells":1285},{"EARLY_PHASE1":1286,"PHASE1":1288,"PHASE2":1290,"PHASE3":1296,"PHASE4":1298,"NA":1300},{"trials":1287,"activeCount":98},[],{"trials":1289,"activeCount":98},[],{"trials":1291,"activeCount":98},[1292],{"nctId":968,"briefTitle":969,"status":120,"phases":1293,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":1294,"interventions":1295},[89],[15,976],[978,979,959,980,981],{"trials":1297,"activeCount":98},[],{"trials":1299,"activeCount":98},[],{"trials":1301,"activeCount":98},[],{"intervention":1303,"totalTrials":177,"cells":1304},"S-1,Docetaxel",{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1309,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1306,"activeCount":98},[],{"trials":1308,"activeCount":98},[],{"trials":1310,"activeCount":98},[1311],{"nctId":1312,"briefTitle":1313,"status":120,"phases":1314,"primaryCompletion":1315,"completion":642,"start":160,"enrollment":1316,"conditions":1317,"interventions":1318},"NCT00587145","Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer",[89],"2009-03",44,[35],[1303],{"trials":1320,"activeCount":98},[],{"trials":1322,"activeCount":98},[],{"trials":1324,"activeCount":98},[],{"intervention":1326,"totalTrials":177,"cells":1327},"Methylprednisolone sodium succinate",{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1346,"PHASE4":1348,"NA":1350},{"trials":1329,"activeCount":98},[],{"trials":1331,"activeCount":98},[],{"trials":1333,"activeCount":98},[1334],{"nctId":1335,"briefTitle":1336,"status":106,"phases":1337,"completion":1338,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1345},"NCT00290602","Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome",[89],"2006-12","2004-02",40,[1342,1343,1344],"Acute Respiratory Distress Syndrome","Acute Lung Injury","Postoperative Complications",[1326],{"trials":1347,"activeCount":98},[],{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[],{"intervention":1353,"totalTrials":177,"cells":1354},"CKD-702 in combination with irinotecan",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1370,"PHASE4":1372,"NA":1374},{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[1361],{"nctId":1362,"briefTitle":1363,"status":120,"phases":1364,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1340,"conditions":1368,"interventions":1369},"NCT05750290","CKD-702 Plus Irinotecan in Gastric Cancer",[89],"2024-12-31","2025-12-31","2022-12-01",[18],[1353],{"trials":1371,"activeCount":98},[],{"trials":1373,"activeCount":98},[],{"trials":1375,"activeCount":98},[],{"intervention":1377,"totalTrials":177,"cells":1378},"Intravesical 2000mg\u002F52.6ml gemcitabine instillation",{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1395,"PHASE4":1397,"NA":1399},{"trials":1380,"activeCount":98},[],{"trials":1382,"activeCount":98},[],{"trials":1384,"activeCount":98},[1385],{"nctId":1386,"briefTitle":1387,"status":120,"phases":1388,"primaryCompletion":1389,"completion":1389,"start":1390,"enrollment":1391,"conditions":1392,"interventions":1394},"NCT03062059","The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence",[89],"2022-12-31","2018-03-01",134,[1393],"Urothelial Carcinoma",[1377],{"trials":1396,"activeCount":98},[],{"trials":1398,"activeCount":98},[],{"trials":1400,"activeCount":98},[],{"intervention":1068,"totalTrials":177,"cells":1402},{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1413,"PHASE4":1415,"NA":1417},{"trials":1404,"activeCount":98},[],{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[1409],{"nctId":1059,"briefTitle":1060,"status":120,"phases":1410,"primaryCompletion":1062,"completion":1062,"start":1063,"enrollment":1064,"conditions":1411,"interventions":1412},[89],[20,1066],[1050,1068,1069],{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[],{"trials":1418,"activeCount":98},[],{"intervention":1069,"totalTrials":177,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1422,"activeCount":98},[],{"trials":1424,"activeCount":98},[],{"trials":1426,"activeCount":98},[1427],{"nctId":1059,"briefTitle":1060,"status":120,"phases":1428,"primaryCompletion":1062,"completion":1062,"start":1063,"enrollment":1064,"conditions":1429,"interventions":1430},[89],[20,1066],[1050,1068,1069],{"trials":1432,"activeCount":98},[],{"trials":1434,"activeCount":98},[],{"trials":1436,"activeCount":98},[],{"intervention":128,"totalTrials":177,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1440,"activeCount":98},[],{"trials":1442,"activeCount":98},[],{"trials":1444,"activeCount":98},[1445],{"nctId":118,"briefTitle":119,"status":120,"phases":1446,"primaryCompletion":122,"start":123,"enrollment":124,"conditions":1447,"interventions":1448},[89],[20],[127,128],{"trials":1450,"activeCount":98},[],{"trials":1452,"activeCount":98},[],{"trials":1454,"activeCount":98},[],{"intervention":140,"totalTrials":177,"cells":1456},{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1458,"activeCount":98},[],{"trials":1460,"activeCount":98},[],{"trials":1462,"activeCount":98},[1463],{"nctId":130,"briefTitle":131,"status":120,"phases":1464,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":1465,"interventions":1466},[88,89],[138],[115,77,140],{"trials":1468,"activeCount":98},[],{"trials":1470,"activeCount":98},[],{"trials":1472,"activeCount":98},[],{"intervention":1474,"totalTrials":177,"cells":1475},"Herzuma",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1492,"PHASE4":1494,"NA":1496},{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[],{"trials":1481,"activeCount":98},[1482],{"nctId":1483,"briefTitle":1484,"status":106,"phases":1485,"primaryCompletion":1486,"completion":1075,"start":1487,"enrollment":1488,"conditions":1489,"interventions":1491},"NCT03755141","Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer",[89],"2021-08-24","2018-12-15",109,[1490,32],"HER2-positive Breast Cancer",[1474],{"trials":1493,"activeCount":98},[],{"trials":1495,"activeCount":98},[],{"trials":1497,"activeCount":98},[],{"intervention":1499,"totalTrials":177,"cells":1500},"Brentuximab vedotin",{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1502,"activeCount":98},[],{"trials":1504,"activeCount":98},[],{"trials":1506,"activeCount":98},[1507],{"nctId":1508,"briefTitle":1509,"status":120,"phases":1510,"primaryCompletion":1511,"completion":1512,"start":1513,"enrollment":419,"conditions":1514,"interventions":1516},"NCT05243693","Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma",[89],"2024-02-28","2026-03-31","2022-03",[1515],"Relapsed\u002FRefractory Classical Hodgkin Lymphoma",[1499],{"trials":1518,"activeCount":98},[],{"trials":1520,"activeCount":98},[],{"trials":1522,"activeCount":98},[],{"intervention":1159,"totalTrials":177,"cells":1524},{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1526,"activeCount":98},[],{"trials":1528,"activeCount":98},[],{"trials":1530,"activeCount":98},[1531],{"nctId":1152,"briefTitle":1153,"status":1154,"phases":1532,"primaryCompletion":1156,"completion":135,"start":665,"enrollment":98,"conditions":1533,"interventions":1534},[89],[15],[1159,310],{"trials":1536,"activeCount":98},[],{"trials":1538,"activeCount":98},[],{"trials":1540,"activeCount":98},[],{"intervention":1542,"totalTrials":177,"cells":1543},"Lapatinib",{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1559,"PHASE4":1561,"NA":1563},{"trials":1545,"activeCount":98},[],{"trials":1547,"activeCount":98},[],{"trials":1549,"activeCount":98},[1550],{"nctId":1551,"briefTitle":1552,"status":120,"phases":1553,"primaryCompletion":765,"completion":765,"start":1554,"enrollment":1555,"conditions":1556,"interventions":1557},"NCT01730677","Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib\u002FTrastuzumab",[89],"2012-07",150,[32],[1542,1558],"Vinorelbine",{"trials":1560,"activeCount":98},[],{"trials":1562,"activeCount":98},[],{"trials":1564,"activeCount":98},[],{"intervention":1558,"totalTrials":177,"cells":1566},{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1568,"activeCount":98},[],{"trials":1570,"activeCount":98},[],{"trials":1572,"activeCount":98},[1573],{"nctId":1551,"briefTitle":1552,"status":120,"phases":1574,"primaryCompletion":765,"completion":765,"start":1554,"enrollment":1555,"conditions":1575,"interventions":1576},[89],[32],[1542,1558],{"trials":1578,"activeCount":98},[],{"trials":1580,"activeCount":98},[],{"trials":1582,"activeCount":98},[],{"intervention":1584,"totalTrials":177,"cells":1585},"Study treatment",{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1601,"PHASE4":1603,"NA":1605},{"trials":1587,"activeCount":98},[],{"trials":1589,"activeCount":98},[],{"trials":1591,"activeCount":98},[1592],{"nctId":1593,"briefTitle":1594,"status":120,"phases":1595,"primaryCompletion":1596,"completion":1597,"start":1196,"enrollment":445,"conditions":1598,"interventions":1600},"NCT01027676","Study of Vorinostat and Gefitinib in Relapsed\u002F or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)",[88,89],"2013-12","2014-03",[1599],"Non-Small-Cell Lung Carcinoma",[1584],{"trials":1602,"activeCount":98},[],{"trials":1604,"activeCount":98},[],{"trials":1606,"activeCount":98},[],{"intervention":1608,"totalTrials":177,"cells":1609},"Sorafenib",{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1623,"PHASE4":1625,"NA":1627},{"trials":1611,"activeCount":98},[],{"trials":1613,"activeCount":98},[],{"trials":1615,"activeCount":98},[1616],{"nctId":1617,"briefTitle":1618,"status":144,"phases":1619,"primaryCompletion":1620,"completion":352,"start":361,"enrollment":21,"conditions":1621,"interventions":1622},"NCT01159327","Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy",[89],"2013-04",[113],[1608],{"trials":1624,"activeCount":98},[],{"trials":1626,"activeCount":98},[],{"trials":1628,"activeCount":98},[],{"intervention":1630,"totalTrials":177,"cells":1631},"Helicobacter pylori eradication",{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1647,"PHASE4":1649,"NA":1651},{"trials":1633,"activeCount":98},[],{"trials":1635,"activeCount":98},[],{"trials":1637,"activeCount":98},[1638],{"nctId":1639,"briefTitle":1640,"status":106,"phases":1641,"primaryCompletion":1642,"completion":1315,"start":1643,"enrollment":1644,"conditions":1645,"interventions":1646},"NCT01002443","Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer",[89],"2006-03","2003-07",190,[18],[1630],{"trials":1648,"activeCount":98},[],{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":98},[],{"intervention":1654,"totalTrials":177,"cells":1655},"Capecitabine Oxaliplatin",{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1660,"PHASE3":1671,"PHASE4":1673,"NA":1675},{"trials":1657,"activeCount":98},[],{"trials":1659,"activeCount":98},[],{"trials":1661,"activeCount":98},[1662],{"nctId":1663,"briefTitle":1664,"status":120,"phases":1665,"primaryCompletion":1666,"completion":1667,"start":244,"enrollment":1028,"conditions":1668,"interventions":1670},"NCT01952951","Preoperative Chemoradiation Followed by Chemotherapy for Locally Advanced Rectal Cancer",[89],"2017-09","2019-12",[1669,625],"Rectal Neoplasms",[1654],{"trials":1672,"activeCount":98},[],{"trials":1674,"activeCount":98},[],{"trials":1676,"activeCount":98},[],{"intervention":1678,"totalTrials":177,"cells":1679},"sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid",{"EARLY_PHASE1":1680,"PHASE1":1682,"PHASE2":1684,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1681,"activeCount":98},[],{"trials":1683,"activeCount":98},[],{"trials":1685,"activeCount":98},[1686],{"nctId":1687,"briefTitle":1688,"status":106,"phases":1689,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":1693,"interventions":1697},"NCT02979223","Combination Method Using Sodium Picosulfate and Magnesium Citrate and PEG With Ascorbic Acid for Bowel Preparation",[89],"2017-06","2016-11",142,[1694,1695,1696],"Bowel Preparation","Sodium Picosulfate and Magnesium Citrate","Polyethylene Glycol With Ascorbic Acid",[1678],{"trials":1699,"activeCount":98},[],{"trials":1701,"activeCount":98},[],{"trials":1703,"activeCount":98},[],{"intervention":1705,"totalTrials":177,"cells":1706},"intravesical mitomycin-C 40mg\u002F20ml instillation",{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1711,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1708,"activeCount":98},[],{"trials":1710,"activeCount":98},[],{"trials":1712,"activeCount":98},[1713],{"nctId":1714,"briefTitle":1715,"status":106,"phases":1716,"primaryCompletion":1717,"completion":1389,"start":1718,"enrollment":1719,"conditions":1720,"interventions":1721},"NCT03058757","The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation",[89],"2021-02-18","2017-02-01",71,[326],[1705],{"trials":1723,"activeCount":98},[],{"trials":1725,"activeCount":98},[],{"trials":1727,"activeCount":98},[],{"intervention":1729,"totalTrials":177,"cells":1730},"Anti-EGFR antibody in combination with weekly paclitaxel",{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1747,"PHASE4":1749,"NA":1751},{"trials":1732,"activeCount":98},[],{"trials":1734,"activeCount":98},[],{"trials":1736,"activeCount":98},[1737],{"nctId":1738,"briefTitle":1739,"status":120,"phases":1740,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":1743,"conditions":1744,"interventions":1746},"NCT04077255","EGFR-targeted Therapy for Gastric Cancer",[89],"2023-12-31","2019-09-01",19,[1745],"Adenocarcinoma of the Stomach",[1729],{"trials":1748,"activeCount":98},[],{"trials":1750,"activeCount":98},[],{"trials":1752,"activeCount":98},[],{"intervention":152,"totalTrials":177,"cells":1754},{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1756,"activeCount":98},[],{"trials":1758,"activeCount":98},[],{"trials":1760,"activeCount":98},[1761],{"nctId":142,"briefTitle":143,"status":144,"phases":1762,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":1763,"interventions":1764},[88,89],[32],[152,153,77],{"trials":1766,"activeCount":98},[],{"trials":1768,"activeCount":98},[],{"trials":1770,"activeCount":98},[],{"intervention":1772,"totalTrials":177,"cells":1773},"S-1, capecitabine",{"EARLY_PHASE1":1774,"PHASE1":1776,"PHASE2":1778,"PHASE3":1788,"PHASE4":1790,"NA":1792},{"trials":1775,"activeCount":98},[],{"trials":1777,"activeCount":98},[],{"trials":1779,"activeCount":98},[1780],{"nctId":1781,"briefTitle":1782,"status":120,"phases":1783,"primaryCompletion":304,"completion":1196,"start":1784,"enrollment":1785,"conditions":1786,"interventions":1787},"NCT00580359","S-1 vs Capecitabine in the Elderly and\u002For Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer",[89],"2007-05",96,[35],[1772],{"trials":1789,"activeCount":98},[],{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[],{"intervention":1795,"totalTrials":177,"cells":1796},"Capecitabine, Irinotecan",{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1814,"PHASE4":1816,"NA":1818},{"trials":1798,"activeCount":98},[],{"trials":1800,"activeCount":98},[],{"trials":1802,"activeCount":98},[1803],{"nctId":1804,"briefTitle":1805,"status":120,"phases":1806,"completion":1807,"start":1808,"enrollment":1809,"conditions":1810,"interventions":1813},"NCT00506623","Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer",[89],"2008-12","2004-07",48,[1811,1812],"Rectal Neoplasm","Neoadjuvant Therapy",[1795],{"trials":1815,"activeCount":98},[],{"trials":1817,"activeCount":98},[],{"trials":1819,"activeCount":98},[],{"intervention":627,"totalTrials":177,"cells":1821},{"EARLY_PHASE1":1822,"PHASE1":1824,"PHASE2":1826,"PHASE3":1832,"PHASE4":1834,"NA":1836},{"trials":1823,"activeCount":98},[],{"trials":1825,"activeCount":98},[],{"trials":1827,"activeCount":98},[1828],{"nctId":616,"briefTitle":617,"status":120,"phases":1829,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":1830,"interventions":1831},[89],[624,625],[607,627],{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[],{"intervention":1839,"totalTrials":177,"cells":1840},"S-1, Docetaxel",{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1842,"activeCount":98},[],{"trials":1844,"activeCount":98},[],{"trials":1846,"activeCount":98},[1847],{"nctId":1848,"briefTitle":1849,"status":106,"phases":1850,"primaryCompletion":1851,"completion":1851,"start":1852,"enrollment":1853,"conditions":1854,"interventions":1855},"NCT00980382","A Phase I\u002FII Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma",[88,89],"2007-08","2004-09",85,[35],[1839],{"trials":1857,"activeCount":98},[],{"trials":1859,"activeCount":98},[],{"trials":1861,"activeCount":98},[],{"intervention":1863,"totalTrials":177,"cells":1864},"Ferinject",{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1866,"activeCount":98},[],{"trials":1868,"activeCount":98},[],{"trials":1870,"activeCount":98},[1871],{"nctId":1872,"briefTitle":1873,"status":106,"phases":1874,"primaryCompletion":1875,"completion":1875,"start":1876,"enrollment":1340,"conditions":1877,"interventions":1878},"NCT02628860","Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy",[89],"2020-04-27","2014-01",[23,814],[1863],{"trials":1880,"activeCount":98},[],{"trials":1882,"activeCount":98},[],{"trials":1884,"activeCount":98},[],{"intervention":1886,"totalTrials":177,"cells":1887},"sunitinib",{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1892,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1889,"activeCount":98},[],{"trials":1891,"activeCount":98},[],{"trials":1893,"activeCount":98},[1894],{"nctId":1895,"briefTitle":1896,"status":106,"phases":1897,"primaryCompletion":1898,"completion":1899,"start":1900,"enrollment":600,"conditions":1901,"interventions":1902},"NCT00620347","Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer",[89],"2012-02","2012-09","2008-03",[20],[1886],{"trials":1904,"activeCount":98},[],{"trials":1906,"activeCount":98},[],{"trials":1908,"activeCount":98},[],{"intervention":1910,"totalTrials":177,"cells":1911},"Lorlatinib",{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1916,"PHASE3":1926,"PHASE4":1928,"NA":1930},{"trials":1913,"activeCount":98},[],{"trials":1915,"activeCount":98},[],{"trials":1917,"activeCount":98},[1918],{"nctId":1919,"briefTitle":1920,"status":120,"phases":1921,"primaryCompletion":1389,"completion":1741,"start":1922,"enrollment":307,"conditions":1923,"interventions":1925},"NCT03612154","Study of Lorlatinib in ROS1 Rearranged NSCLC",[89],"2019-05-02",[1924],"Nonsmall Cell Lung Cancer",[1910],{"trials":1927,"activeCount":98},[],{"trials":1929,"activeCount":98},[],{"trials":1931,"activeCount":98},[],{"intervention":1933,"totalTrials":177,"cells":1934},"Paclitaxel\u002FGemcitabine",{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1949,"PHASE4":1951,"NA":1953},{"trials":1936,"activeCount":98},[],{"trials":1938,"activeCount":98},[],{"trials":1940,"activeCount":98},[1941],{"nctId":1942,"briefTitle":1943,"status":144,"phases":1944,"primaryCompletion":110,"completion":1945,"start":1946,"enrollment":1316,"conditions":1947,"interventions":1948},"NCT00532285","Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer",[89],"2009-08","2005-09",[15],[1933],{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":98},[],{"trials":1954,"activeCount":98},[],{"intervention":1129,"totalTrials":177,"cells":1956},{"EARLY_PHASE1":1957,"PHASE1":1959,"PHASE2":1961,"PHASE3":1967,"PHASE4":1969,"NA":1971},{"trials":1958,"activeCount":98},[],{"trials":1960,"activeCount":98},[],{"trials":1962,"activeCount":98},[1963],{"nctId":1119,"briefTitle":1120,"status":106,"phases":1964,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":1125,"conditions":1965,"interventions":1966},[89],[15],[1128,1129],{"trials":1968,"activeCount":98},[],{"trials":1970,"activeCount":98},[],{"trials":1972,"activeCount":98},[],{"intervention":992,"totalTrials":177,"cells":1974},{"EARLY_PHASE1":1975,"PHASE1":1977,"PHASE2":1979,"PHASE3":1985,"PHASE4":1987,"NA":1989},{"trials":1976,"activeCount":98},[],{"trials":1978,"activeCount":98},[],{"trials":1980,"activeCount":98},[1981],{"nctId":983,"briefTitle":984,"status":120,"phases":1982,"primaryCompletion":986,"completion":315,"start":987,"enrollment":988,"conditions":1983,"interventions":1984},[89],[18],[991,992,993],{"trials":1986,"activeCount":98},[],{"trials":1988,"activeCount":98},[],{"trials":1990,"activeCount":98},[],{"intervention":993,"totalTrials":177,"cells":1992},{"EARLY_PHASE1":1993,"PHASE1":1995,"PHASE2":1997,"PHASE3":2003,"PHASE4":2005,"NA":2007},{"trials":1994,"activeCount":98},[],{"trials":1996,"activeCount":98},[],{"trials":1998,"activeCount":98},[1999],{"nctId":983,"briefTitle":984,"status":120,"phases":2000,"primaryCompletion":986,"completion":315,"start":987,"enrollment":988,"conditions":2001,"interventions":2002},[89],[18],[991,992,993],{"trials":2004,"activeCount":98},[],{"trials":2006,"activeCount":98},[],{"trials":2008,"activeCount":98},[],{"intervention":2010,"totalTrials":177,"cells":2011},"Oral Sulfate",{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2016,"PHASE3":2028,"PHASE4":2030,"NA":2032},{"trials":2013,"activeCount":98},[],{"trials":2015,"activeCount":98},[],{"trials":2017,"activeCount":98},[2018],{"nctId":2019,"briefTitle":2020,"status":120,"phases":2021,"primaryCompletion":1074,"completion":1074,"start":2022,"enrollment":2023,"conditions":2024,"interventions":2026},"NCT04593446","Difference of Surgical Site Infection Between Using Sodium Picosulfate Solution(PicosolutionⓇ) and Oral Sulfate Tablet(ORA·FANGⓇ) in Colorectal Cancer Surgery",[89],"2020-11-01",414,[2025],"Colorectal Cancer",[2010,2027],"Sodium Picosulfate Solution",{"trials":2029,"activeCount":98},[],{"trials":2031,"activeCount":98},[],{"trials":2033,"activeCount":98},[],{"intervention":2027,"totalTrials":177,"cells":2035},{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2040,"PHASE3":2046,"PHASE4":2048,"NA":2050},{"trials":2037,"activeCount":98},[],{"trials":2039,"activeCount":98},[],{"trials":2041,"activeCount":98},[2042],{"nctId":2019,"briefTitle":2020,"status":120,"phases":2043,"primaryCompletion":1074,"completion":1074,"start":2022,"enrollment":2023,"conditions":2044,"interventions":2045},[89],[2025],[2010,2027],{"trials":2047,"activeCount":98},[],{"trials":2049,"activeCount":98},[],{"trials":2051,"activeCount":98},[],{"intervention":2053,"totalTrials":177,"cells":2054},"CA and Nivolumab",{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2059,"PHASE3":2070,"PHASE4":2072,"NA":2074},{"trials":2056,"activeCount":98},[],{"trials":2058,"activeCount":98},[],{"trials":2060,"activeCount":98},[2061],{"nctId":2062,"briefTitle":2063,"status":120,"phases":2064,"primaryCompletion":2065,"completion":2065,"start":2066,"enrollment":2067,"conditions":2068,"interventions":2069},"NCT03808480","Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1\u003C10%",[89],"2022-05-31","2019-01-23",22,[1040],[2053],{"trials":2071,"activeCount":98},[],{"trials":2073,"activeCount":98},[],{"trials":2075,"activeCount":98},[],{"intervention":1031,"totalTrials":177,"cells":2077},{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2088,"PHASE4":2090,"NA":2092},{"trials":2079,"activeCount":98},[],{"trials":2081,"activeCount":98},[],{"trials":2083,"activeCount":98},[2084],{"nctId":1023,"briefTitle":1024,"status":106,"phases":2085,"primaryCompletion":1026,"completion":1027,"start":160,"enrollment":1028,"conditions":2086,"interventions":2087},[89],[20],[1010,1031],{"trials":2089,"activeCount":98},[],{"trials":2091,"activeCount":98},[],{"trials":2093,"activeCount":98},[],{"intervention":2095,"totalTrials":177,"cells":2096},"Cefotetan",{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2111,"PHASE4":2113,"NA":2115},{"trials":2098,"activeCount":98},[],{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[2103],{"nctId":2104,"briefTitle":2105,"status":106,"phases":2106,"primaryCompletion":133,"completion":133,"start":1037,"enrollment":2107,"conditions":2108,"interventions":2110},"NCT01220661","Safety and Efficacy of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery",[89],312,[2109],"Colorectal Surgery",[2095],{"trials":2112,"activeCount":98},[],{"trials":2114,"activeCount":98},[],{"trials":2116,"activeCount":98},[],{"intervention":2118,"totalTrials":177,"cells":2119},"Gemcitabine plus Vinorelbine",{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2135,"PHASE4":2137,"NA":2139},{"trials":2121,"activeCount":98},[],{"trials":2123,"activeCount":98},[],{"trials":2125,"activeCount":98},[2126],{"nctId":2127,"briefTitle":2128,"status":106,"phases":2129,"primaryCompletion":1185,"completion":2130,"start":2131,"enrollment":324,"conditions":2132,"interventions":2133},"NCT00532623","Phase II Study of Gemcitabine\u002FVinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer",[89],"2006-10","2004-05",[32],[2118,2134],"Sequential",{"trials":2136,"activeCount":98},[],{"trials":2138,"activeCount":98},[],{"trials":2140,"activeCount":98},[],{"intervention":2134,"totalTrials":177,"cells":2142},{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":2144,"activeCount":98},[],{"trials":2146,"activeCount":98},[],{"trials":2148,"activeCount":98},[2149],{"nctId":2127,"briefTitle":2128,"status":106,"phases":2150,"primaryCompletion":1185,"completion":2130,"start":2131,"enrollment":324,"conditions":2151,"interventions":2152},[89],[32],[2118,2134],{"trials":2154,"activeCount":98},[],{"trials":2156,"activeCount":98},[],{"trials":2158,"activeCount":98},[],{"intervention":2160,"totalTrials":177,"cells":2161},"Norzyme",{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2166,"PHASE3":2176,"PHASE4":2178,"NA":2180},{"trials":2163,"activeCount":98},[],{"trials":2165,"activeCount":98},[],{"trials":2167,"activeCount":98},[2168],{"nctId":2169,"briefTitle":2170,"status":106,"phases":2171,"primaryCompletion":159,"completion":159,"start":2172,"enrollment":2173,"conditions":2174,"interventions":2175},"NCT01587534","Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)",[89],"2011-10",67,[23],[2160],{"trials":2177,"activeCount":98},[],{"trials":2179,"activeCount":98},[],{"trials":2181,"activeCount":98},[],{"intervention":2183,"totalTrials":177,"cells":2184},"Nivolumab",{"EARLY_PHASE1":2185,"PHASE1":2187,"PHASE2":2189,"PHASE3":2200,"PHASE4":2202,"NA":2204},{"trials":2186,"activeCount":98},[],{"trials":2188,"activeCount":98},[],{"trials":2190,"activeCount":98},[2191],{"nctId":2192,"briefTitle":2193,"status":106,"phases":2194,"primaryCompletion":2195,"completion":2196,"start":2197,"enrollment":445,"conditions":2198,"interventions":2199},"NCT04611165","Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC",[89],"2022-12-30","2023-12-15","2019-11-15",[447],[2183],{"trials":2201,"activeCount":98},[],{"trials":2203,"activeCount":98},[],{"trials":2205,"activeCount":98},[],{"intervention":2207,"totalTrials":177,"cells":2208},"IP chemotherapy",{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2210,"activeCount":98},[],{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":98},[2215],{"nctId":2216,"briefTitle":2217,"status":120,"phases":2218,"primaryCompletion":2219,"completion":1389,"start":949,"enrollment":2220,"conditions":2221,"interventions":2223},"NCT01441349","Irinotecan\u002FCisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer",[89],"2022-10-31",192,[2222],"Small Cell Lung Carcinoma",[2207,2224],"IP chemotherapy plus simvastatin",{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[],{"intervention":2224,"totalTrials":177,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2243,"PHASE4":2245,"NA":2247},{"trials":2234,"activeCount":98},[],{"trials":2236,"activeCount":98},[],{"trials":2238,"activeCount":98},[2239],{"nctId":2216,"briefTitle":2217,"status":120,"phases":2240,"primaryCompletion":2219,"completion":1389,"start":949,"enrollment":2220,"conditions":2241,"interventions":2242},[89],[2222],[2207,2224],{"trials":2244,"activeCount":98},[],{"trials":2246,"activeCount":98},[],{"trials":2248,"activeCount":98},[],{"intervention":2250,"totalTrials":177,"cells":2251},"Concurrent chemoradiation therapy",{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2266,"PHASE4":2268,"NA":2270},{"trials":2253,"activeCount":98},[],{"trials":2255,"activeCount":98},[],{"trials":2257,"activeCount":98},[2258],{"nctId":2259,"briefTitle":2260,"status":120,"phases":2261,"primaryCompletion":133,"completion":134,"start":110,"enrollment":2262,"conditions":2263,"interventions":2264},"NCT00452803","Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)",[89],102,[20],[2265,2250],"chemotherapy",{"trials":2267,"activeCount":98},[],{"trials":2269,"activeCount":98},[],{"trials":2271,"activeCount":98},[],{"intervention":2273,"totalTrials":177,"cells":2274},"IP",{"EARLY_PHASE1":2275,"PHASE1":2277,"PHASE2":2279,"PHASE3":2291,"PHASE4":2293,"NA":2295},{"trials":2276,"activeCount":98},[],{"trials":2278,"activeCount":98},[],{"trials":2280,"activeCount":98},[2281],{"nctId":2282,"briefTitle":2283,"status":106,"phases":2284,"primaryCompletion":2285,"completion":2285,"start":2286,"enrollment":2287,"conditions":2288,"interventions":2289},"NCT01003964","Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB\u002FIV",[89],"2015-06","2009-02",289,[624],[2273,2290],"GP",{"trials":2292,"activeCount":98},[],{"trials":2294,"activeCount":98},[],{"trials":2296,"activeCount":98},[],{"intervention":2290,"totalTrials":177,"cells":2298},{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2309,"PHASE4":2311,"NA":2313},{"trials":2300,"activeCount":98},[],{"trials":2302,"activeCount":98},[],{"trials":2304,"activeCount":98},[2305],{"nctId":2282,"briefTitle":2283,"status":106,"phases":2306,"primaryCompletion":2285,"completion":2285,"start":2286,"enrollment":2287,"conditions":2307,"interventions":2308},[89],[624],[2273,2290],{"trials":2310,"activeCount":98},[],{"trials":2312,"activeCount":98},[],{"trials":2314,"activeCount":98},[],{"intervention":2316,"totalTrials":177,"cells":2317},"Letrozole ,Goserelin",{"EARLY_PHASE1":2318,"PHASE1":2320,"PHASE2":2322,"PHASE3":2332,"PHASE4":2334,"NA":2336},{"trials":2319,"activeCount":98},[],{"trials":2321,"activeCount":98},[],{"trials":2323,"activeCount":98},[2324],{"nctId":2325,"briefTitle":2326,"status":106,"phases":2327,"primaryCompletion":999,"completion":2328,"start":634,"enrollment":2329,"conditions":2330,"interventions":2331},"NCT00532272","Goserelin\u002FLetrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC",[89],"2010-08",78,[32],[2316],{"trials":2333,"activeCount":98},[],{"trials":2335,"activeCount":98},[],{"trials":2337,"activeCount":98},[],{"intervention":1092,"totalTrials":177,"cells":2339},{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2344,"PHASE3":2350,"PHASE4":2352,"NA":2354},{"trials":2341,"activeCount":98},[],{"trials":2343,"activeCount":98},[],{"trials":2345,"activeCount":98},[2346],{"nctId":1083,"briefTitle":1084,"status":120,"phases":2347,"primaryCompletion":1074,"completion":1086,"start":1087,"enrollment":1088,"conditions":2348,"interventions":2349},[89],[1090],[1092,1050],{"trials":2351,"activeCount":98},[],{"trials":2353,"activeCount":98},[],{"trials":2355,"activeCount":98},[],{"intervention":2357,"totalTrials":177,"cells":2358},"Picolight + Coolprep",{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2374,"PHASE4":2376,"NA":2378},{"trials":2360,"activeCount":98},[],{"trials":2362,"activeCount":98},[],{"trials":2364,"activeCount":98},[2365],{"nctId":2366,"briefTitle":2367,"status":106,"phases":2368,"primaryCompletion":998,"completion":2369,"start":148,"enrollment":2370,"conditions":2371,"interventions":2372},"NCT01919255","Evaluation of PICOLIGHT Plus COOLPREP, PICOLIGHT Plus CLICOLON for Bowel Preparation",[89],"2014-10",236,[908],[2357,2373],"Picolight + Clicolon",{"trials":2375,"activeCount":98},[],{"trials":2377,"activeCount":98},[],{"trials":2379,"activeCount":98},[],{"intervention":2373,"totalTrials":177,"cells":2381},{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2392,"PHASE4":2394,"NA":2396},{"trials":2383,"activeCount":98},[],{"trials":2385,"activeCount":98},[],{"trials":2387,"activeCount":98},[2388],{"nctId":2366,"briefTitle":2367,"status":106,"phases":2389,"primaryCompletion":998,"completion":2369,"start":148,"enrollment":2370,"conditions":2390,"interventions":2391},[89],[908],[2357,2373],{"trials":2393,"activeCount":98},[],{"trials":2395,"activeCount":98},[],{"trials":2397,"activeCount":98},[],{"intervention":2399,"totalTrials":177,"cells":2400},"Irinotecan, Oxaliplatin, TS-1",{"EARLY_PHASE1":2401,"PHASE1":2403,"PHASE2":2405,"PHASE3":2414,"PHASE4":2416,"NA":2418},{"trials":2402,"activeCount":98},[],{"trials":2404,"activeCount":98},[],{"trials":2406,"activeCount":98},[2407],{"nctId":2408,"briefTitle":2409,"status":106,"phases":2410,"primaryCompletion":2411,"completion":2411,"start":665,"enrollment":1316,"conditions":2412,"interventions":2413},"NCT00512681","A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer",[89],"2009-07",[35],[2399],{"trials":2415,"activeCount":98},[],{"trials":2417,"activeCount":98},[],{"trials":2419,"activeCount":98},[],{"intervention":2421,"totalTrials":177,"cells":2422},"S-1,oxaliplatin",{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2427,"PHASE3":2436,"PHASE4":2438,"NA":2440},{"trials":2424,"activeCount":98},[],{"trials":2426,"activeCount":98},[],{"trials":2428,"activeCount":98},[2429],{"nctId":2430,"briefTitle":2431,"status":120,"phases":2432,"primaryCompletion":2328,"completion":2328,"start":665,"enrollment":2433,"conditions":2434,"interventions":2435},"NCT00515190","Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma",[89],198,[35],[2421],{"trials":2437,"activeCount":98},[],{"trials":2439,"activeCount":98},[],{"trials":2441,"activeCount":98},[],{"intervention":2443,"totalTrials":177,"cells":2444},"Cetuximab, Irinotecan, Capecitabine",{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2458,"PHASE4":2460,"NA":2462},{"trials":2446,"activeCount":98},[],{"trials":2448,"activeCount":98},[],{"trials":2450,"activeCount":98},[2451],{"nctId":2452,"briefTitle":2453,"status":120,"phases":2454,"completion":109,"start":160,"enrollment":1340,"conditions":2455,"interventions":2457},"NCT00506844","Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer",[89],[1669,2456],"Neoadjuvant Treatment",[2443],{"trials":2459,"activeCount":98},[],{"trials":2461,"activeCount":98},[],{"trials":2463,"activeCount":98},[],{"intervention":2465,"totalTrials":177,"cells":2466},"Irinotecan plus capecitabine",{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2471,"PHASE3":2481,"PHASE4":2483,"NA":2485},{"trials":2468,"activeCount":98},[],{"trials":2470,"activeCount":98},[],{"trials":2472,"activeCount":98},[2473],{"nctId":2474,"briefTitle":2475,"status":106,"phases":2476,"primaryCompletion":999,"completion":133,"start":2477,"enrollment":8,"conditions":2478,"interventions":2480},"NCT00532714","Phase II Study of Irinotecan\u002FCapecitabine in Patients With Antracycline\u002FTaxane Pretreated MBC",[89],"2006-08",[2479],"Breast Cancer Metastatic",[2465],{"trials":2482,"activeCount":98},[],{"trials":2484,"activeCount":98},[],{"trials":2486,"activeCount":98},[],{"intervention":2488,"totalTrials":177,"cells":2489},"Oxaliplatin-based chemotherapy",{"EARLY_PHASE1":2490,"PHASE1":2492,"PHASE2":2494,"PHASE3":2503,"PHASE4":2505,"NA":2507},{"trials":2491,"activeCount":98},[],{"trials":2493,"activeCount":98},[],{"trials":2495,"activeCount":98},[2496],{"nctId":2497,"briefTitle":2498,"status":120,"phases":2499,"primaryCompletion":352,"completion":1596,"start":1026,"enrollment":667,"conditions":2500,"interventions":2502},"NCT01300156","Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)",[89],[2501],"Hodgkin's Lymphoma",[2488],{"trials":2504,"activeCount":98},[],{"trials":2506,"activeCount":98},[],{"trials":2508,"activeCount":98},[],{"intervention":1042,"totalTrials":177,"cells":2510},{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2515,"PHASE3":2521,"PHASE4":2523,"NA":2525},{"trials":2512,"activeCount":98},[],{"trials":2514,"activeCount":98},[],{"trials":2516,"activeCount":98},[2517],{"nctId":1033,"briefTitle":1034,"status":106,"phases":2518,"primaryCompletion":290,"completion":1036,"start":1037,"enrollment":1038,"conditions":2519,"interventions":2520},[89],[1040],[1042,1010],{"trials":2522,"activeCount":98},[],{"trials":2524,"activeCount":98},[],{"trials":2526,"activeCount":98},[],{"intervention":115,"totalTrials":2528,"cells":2529},4,{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2534,"PHASE3":2548,"PHASE4":2550,"NA":2552},{"trials":2531,"activeCount":98},[],{"trials":2533,"activeCount":98},[],{"trials":2535,"activeCount":98},[2536,2540,2544],{"nctId":104,"briefTitle":105,"status":106,"phases":2537,"primaryCompletion":108,"completion":109,"start":110,"enrollment":111,"conditions":2538,"interventions":2539},[89],[113],[115,77,116],{"nctId":130,"briefTitle":131,"status":120,"phases":2541,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":2542,"interventions":2543},[88,89],[138],[115,77,140],{"nctId":995,"briefTitle":996,"status":120,"phases":2545,"primaryCompletion":998,"completion":159,"start":999,"enrollment":307,"conditions":2546,"interventions":2547},[89],[1001],[959,115],{"trials":2549,"activeCount":98},[],{"trials":2551,"activeCount":98},[],{"trials":2553,"activeCount":98},[2554],{"nctId":2555,"briefTitle":2556,"status":120,"phases":2557,"completion":1807,"start":2477,"enrollment":2558,"conditions":2559,"interventions":2560},"NCT00507143","Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan",[92],100,[669,670],[2561],"irinotecan",{"intervention":2563,"totalTrials":380,"cells":2564},"Chemotherapy",{"EARLY_PHASE1":2565,"PHASE1":2567,"PHASE2":2569,"PHASE3":2575,"PHASE4":2577,"NA":2579},{"trials":2566,"activeCount":98},[],{"trials":2568,"activeCount":98},[],{"trials":2570,"activeCount":98},[2571],{"nctId":2259,"briefTitle":2260,"status":120,"phases":2572,"primaryCompletion":133,"completion":134,"start":110,"enrollment":2262,"conditions":2573,"interventions":2574},[89],[20],[2265,2250],{"trials":2576,"activeCount":98},[],{"trials":2578,"activeCount":98},[],{"trials":2580,"activeCount":98},[2581],{"nctId":2582,"briefTitle":2583,"status":120,"phases":2584,"primaryCompletion":765,"completion":2585,"start":877,"enrollment":2586,"conditions":2587,"interventions":2591},"NCT03062072","Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients",[],"2022-12",300,[2588,2589,15,2590],"Cancer","Colon Cancer","Malignant Lymphoma",[2563],{"intervention":2593,"totalTrials":380,"cells":2594},"Tamoxifen",{"EARLY_PHASE1":2595,"PHASE1":2597,"PHASE2":2599,"PHASE3":2610,"PHASE4":2612,"NA":2614},{"trials":2596,"activeCount":98},[],{"trials":2598,"activeCount":98},[],{"trials":2600,"activeCount":98},[2601],{"nctId":2602,"briefTitle":2603,"status":144,"phases":2604,"primaryCompletion":353,"completion":2605,"start":353,"enrollment":2606,"conditions":2607,"interventions":2609},"NCT00532454","Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen",[89],"2007-12",21,[15,2608],"Metastatic Disease",[2593],{"trials":2611,"activeCount":98},[],{"trials":2613,"activeCount":98},[],{"trials":2615,"activeCount":98},[2616],{"nctId":2617,"briefTitle":2618,"status":120,"phases":2619,"primaryCompletion":2620,"start":2621,"enrollment":2622,"conditions":2623,"interventions":2624},"NCT02488603","Decision Aids for Tamoxifen Treatment in Breast Cancer Patients",[92],"2018-08","2015-08",360,[15],[2625],"tamoxifen",{"intervention":2627,"totalTrials":177,"cells":2628},"standard first line anti-TB drugs",{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2635,"PHASE4":2637,"NA":2639},{"trials":2630,"activeCount":98},[],{"trials":2632,"activeCount":98},[],{"trials":2634,"activeCount":98},[],{"trials":2636,"activeCount":98},[],{"trials":2638,"activeCount":98},[],{"trials":2640,"activeCount":98},[2641],{"nctId":2642,"briefTitle":2643,"status":106,"phases":2644,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":1340,"conditions":2647,"interventions":2650},"NCT01364324","Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients",[],"2020-06","2010-09",[2648,2649,26],"Tuberculosis","Tuberculosis, Pulmonary",[2627]]